- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04428931
Attentional Performance in Parkinson Disease
Evaluation of Attentional Performance in Parkinson Disease
Background:
Parkinson Disease (PD) is a nervous system disorder that affects movement. Dopamine is an important neurotransmitter in the brain. As PD progresses, there is less and less dopamine in the brain. Researchers think there may be a relationship between differences in attention and dopamine in people with PD.
Objective:
To learn if people with PD that is worse on one side also have differences in how much attention they pay to the two sides of space on their left and right.
Eligibility:
English-speaking, right-handed people age 35-80 with PD.
Design:
Participants will be screened with medical and neurological history and exam, and medicine review.
Participants will have 1 study visit. It will last 7-8 hours. They will stop taking their Parkinson medicine 12 hours before the visit.
Participants will complete questionnaires.
Participants will do tasks on a computer screen. They will judge the middle of lines, react to stimuli, and search and identify items that appear on the screen.
Participants may have functional and structural magnetic resonance imaging (MRI). MRI uses a strong magnetic field and radio waves to take pictures of the brain. During the MRI, participants will lie on a table that slides in and out of the MRI scanner. While inside the scanner, they will look at a cross on a screen, relax, and think about nothing.
Participants will undergo prism adaptation. They will sit in front of a board while their chin rests on a support. They will point to 1 of 2 dots on the board while they wear prism glasses that shift their vision to the left or right....
Study Overview
Status
Conditions
Detailed Description
Study Description:
We will investigate the relationship between Dopamine (DA) function and attention in patients with asymmetric Parkinson Disease (PD). We hypothesize that the direction of asymmetry in dopamine (DA) depletion predicts the asymmetry in visual attention.
Objectives:
Primary Objective:
- to study attentional asymmetry in patients with PD. We hypothesize that visual attention in Parkinson will be biased to the visual field contralateral to the least affected hemisphere (i.e. contralateral to the most affected side).
Secondary Objectives:
- to investigate the correlation between feedback learning and visuospatial attention performance in PD. We hypothesize that feedback learning will also be affected according to the most compromised hemisphere. Right hemisphere-predominant PD patients (left-motor predominant), compared to left hemisphere-predominant patients, will exhibit a rightward visuospatial bias and a relative preference for learning from reward, compared to punishment.
- to investigate the effect of prism adaptation on feedback learning and visuospatial attention in PD. This objective is exploratory.
Endpoints:
Primary Endpoint: visuospatial performance on the Landmark Task
Secondary Endpoints: performance on:
- Posner Task
- Visual Search Task
- Attentional blink Task
- Visuospatial performance on the Manual Line Bisection Task
- Reward and Punishment Implicit Feedback Learning Task
- The Attentional Scaling Task
Functional connectivity measured with resting state fMRI.
Study Population:
Sixty patients with asymmetric PD. Any gender, aged 35-80 (inclusive), able to give consent and without a diagnosis of significant illness affecting the central nervous system other than PD.
Study Type
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
INCLUSION CRITERIA:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female aged 35 - 80 (inclusive)
- Fluent in English
- Right-handed per the Edinburgh Handedness scale
- Able to provide consent
- Diagnosis of idiopathic Parkinson s disease according to UK Brain Bank criteria
- On dopaminergic therapy to treat Parkinsonian symptoms
- MOCA Score greater than or equal to 24 determined by a NIH neurologist
- Hoehn and Yahr Score less than or equal to 3 determined by a NIH neurologist
- Asymmetric motor symptoms
EXCLUSION CRITERIA:
- Any current major neurological or psychiatric disorder other than Parkinson s disease, such as, (but not limited to) stroke, dementia, Alzheimer disease, Schizophrenia or Major Depression Disorder
- Inability to provide consent
- Members of the Behavioral Neurology Unit, NINDS
- Left-handed per the Edinburgh Handedness scale
- Primarily axial motor symptoms or symmetrical limb involvement
- Pregnancy
Exclusion criteria for MRI
- Presence of metal which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if subject was a welder or metal worker, since small metal fragments may be present in the eye.
- Claustrophobia
- Inability to lie supine comfortably for 1 hour
- Pregnancy
INCLUSION OF VULNERABLE PARTICIPANTS:
Because the goals of the study can be accomplished without involving vulnerable population, we will not include individuals without consent capacity.
Since the goal is to characterize visuospatial attention deficits in idiopathic PD which is a disease of late adulthood, we will not include children.
The effects of MRI on fetal development and the health of pregnant women is unknown.
Therefore, women who are pregnant and breast-feeding will be excluded and women who can become pregnant will be excluded following a positive pregnancy test, if the optional MRI is under consideration.
The study requires fluency in English in order to completely understand tasks instructions, thus non-English speakers/readers will be excluded.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
PD patients
Patients with Asymmetric Parkinson's disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attentional asymmetry
Time Frame: 2 months
|
Direction and degree of visuospatial bias on the Landmark task
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feedback learning and visuospatial attention performance
Time Frame: 2 months
|
Direction and degree of visuospatial bias on the Manual Line Bisection, Visual Search Posner, Attentional Blink, Reward and Punishment Implicit Feedback Learning, and the Attentional Scaling Tasks
|
2 months
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200102
- 20-N-0102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada